Table 3– Use of inhaled therapies and low-dose azithromycin during 2003, at the participating cystic fibrosis centres# and at the centres with the highest prevalences of Mycobacterium abscessus complex (MABSC) infection
Paediatric centresMixed centresAdult centres
All centres (n=15)Centre A+All centres (n=9)Centre B§All centres (n=10)Centre Cƒ
Subjects n10321025596463341
Treatment
 Inhaled antibiotics36 (29.8–42.3), 13.2–54.33838.7 (28.4–49.0), 21.1–60.92954.7 (44.9–64.4), 30.1–80.052
 Inhaled rhDnase49.7 (37.8–61.6), 2.2–71.81352 (36.2–67.8), 19.2–812552.2 (35.0–69.3), 23.1–96ND
 Inhaled steroids33.3 (24–42.6), 8.3–70.34732.1 (14–50.1), 7.7–72.51630.25 (17.9–42.6), 8–55.139
 Inhaled bronchodilators31.9 (25.1–38.8), 16.1–51.43436.1 (16.6–55.5), 11.5–76.21249.2 (35.0–63.4), 12.2–65.461
 Low dose azithromycin20.9 (13.6–28.1), 6.5–50.52228 (17.1–38.8), 5.8–5020.543.7 (30.9–56.4), 11.8–72.5ND
  • Data are presented as mean (95% CI), range, unless otherwise stated. ND: not determined. #: only centres with at least 20 patients with complete data were taken into account; : for at least 3 consecutive months; +: 7.8% prevalence of MABSC infection at the centre; §: 4.7% prevalence; ƒ: 4.9% prevalence.